指南与共识脑血管病

提高急性卒中试验入组率:现状与共识推荐

Enhancing Enrollment in Acute Stroke Trials: Current State and Consensus Recommendations.
指南 / 共识 · Stroke · 2023-09-11

STAIR XII会议于2023年3月22日召开专题研讨会,汇集卒中医师、研究人员、NINDS成员、工业界代表及FDA成员,讨论急性卒中试验入组现状与改进机会。会议识别了影响入组的关键问题并提出行动事项,包括紧急知情同意、入组标准、非工作时间人员可用性、试验热情与均势、站点启动、站点冠军、将研究流程纳入标准工作流、远程站点集中入组、全球试验及可行时共同入组。结论强调入组是急性卒中试验的生命线,应拓宽紧急知情同意程序的理解与实施,并采用易纳入标准工作流的设计与流程。

要点

  • 紧急知情同意程序的推广与实施是提高急性卒中试验入组的关键行动方向。
  • 应审慎考虑入组标准以最大化入组并提高代表性。
  • 采用易纳入标准工作流的设计与流程可提高试验效率与执行。

核心结论

  • 入组是急性卒中试验的生命线,也是测试改善患者预后新方法的限速步骤。
  • 应努力拓宽医学界对紧急知情同意程序的理解与实施。
  • 应采用易纳入标准工作流并提高试验效率与执行的设计与流程。
  • 改善入组的研究与行动对卒中预后的广泛改善将超过任何单一正在考虑的治疗。

研究设计与样本

  • 卒中治疗学术产业圆桌会议(STAIR)在2023年3月22日STAIR XII会议上就急性卒中试验入组召开会议与研讨会。
  • 论坛汇集卒中医师与研究人员、美国国家神经疾病与卒中研究所成员、工业界代表及美国食品药品监督管理局成员。
  • 研讨会识别了影响急性卒中试验入组的最相关问题并针对每个问题提出潜在行动事项。

主要发现

  • 重点领域包括美国的紧急知情同意及其他国家的紧急知情同意。
  • 重点领域包括审慎考虑入组标准以最大化入组并提高代表性。
  • 重点领域包括研究者、研究协调员和药师在非工作时间的可用性。
  • 重点领域包括试验热情与均势、站点启动包括合同问题、站点冠军。
  • 重点领域包括尽可能将研究流程纳入标准工作流、远程站点由研究团队使用远程医疗集中入组、全球试验及可行时共同入组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Stroke Treatment Academic Industry Roundtable (STAIR) convened a session and workshop regarding enrollment in acute stroke trials during the STAIR XII meeting on March 22, 2023. This forum brought together stroke physicians and researchers, members of the National Institute of Neurological Disorders and Stroke, industry representatives, and members of the US Food and Drug Administration to discuss the current status and opportunities for improving enrollment in acute stroke trials. The workshop identified the most relevant issues impacting enrollment in acute stroke trials and addressed potential action items for each. Focus areas included emergency consent in the United States and other countries; careful consideration of eligibility criteria to maximize enrollment and representativeness; investigator, study coordinator, and pharmacist availability outside of business hours; trial enthusiasm/equipoise; site start-up including contractual issues; site champions; incorporation of study procedures into standard workflow as much as possible; centralized enrollment at remote sites by study teams using telemedicine; global trials; and coenrollment in trials when feasible. In conclusion, enrollment of participants is the lifeblood of acute stroke trials and is the rate-limiting step for testing an exciting array of new approaches to improve patient outcomes. In particular, efforts should be undertaken to broaden the medical community's understanding and implementation of emergency consent procedures and to adopt designs and processes that are easily incorporated into standard workflow and that improve trials' efficiencies and execution. Research and actions to improve enrollment in ongoing and future trials will improve stroke outcomes more broadly than any single therapy under consideration.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Broderick JP, Silva GS, Selim M, et al. Enhancing Enrollment in Acute Stroke Trials: Current State and Consensus Recommendations. Stroke. 2023. PMID: 37694403. doi:10.1161/STROKEAHA.123.044149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。